2.04  -0.11 (-5.12%)		08-18 16:00
Open: 2.15 High: 2.15 Volume: 2,285,257		Pre. Close: 2.15 Low: 2.01 Market Cap: 354(M)

Short term
Mid term
Targets	6-month :	2.59	1-year :	3.02
Resists	First :	2.22	Second :	2.59
Pivot price	2.05
Supports	First :	1.98	Second :	1.84
MAs	MA(5) :	2.08	MA(20) :	2.03
	MA(100) :	1.97	MA(250) :	1.77
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	72.6	D(3) :	76
RSI	RSI(14): 50.3
52-week	High :	2.85	Low :	0.52

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PALI ] has closed above bottom band by 45.5%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.16 - 2.17	2.17 - 2.17
Low:	1.98 - 2	2 - 2.01
Close:	2.02 - 2.04	2.04 - 2.06

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.

Mon, 17 Aug 2026
Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - tradingview.com

Fri, 14 Aug 2026
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan

Fri, 14 Aug 2026
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Thu, 13 Aug 2026
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan

Mon, 10 Aug 2026
Palisade Bio Reports Second Quarter 2026 Financial Results - GlobeNewswire

Mon, 10 Aug 2026
PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary - tradingview.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	174 (M)
Shares Float	133 (M)
Held by Insiders	1.6 (%)
Held by Institutions	100.5 (%)
Shares Short	37,020 (K)
Shares Short P.Month	31,520 (K)

EPS	0.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.75
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-23.4 %
Return on Equity (ttm)	-36.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.16
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	17
PEG Ratio	0
Price to Book value	2.68
Price to Sales	0
Price to Cash Flow	-28.56

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.